Abstract
Objective: To determine the effect of rimonabant on energy expenditure (O2 consumption) in rats at different metabolic states and in cannabinoid CB1 receptor-deficient (CB1R−/−) mice.
Design: Animals were exposed to light–dark cycles and fed only during dark cycles. Rimonabant or vehicle was administered together with food (absorptive), following overnight feeding (postabsorptive) or following a whole day of no food (fasting). Indirect calorimetric measurements, physical activity and food intake were measured continuously.
Results: Compared with vehicle-treated rats, rats administered 3 and 10 mg kg−1 rimonabant showed an 18 and 49% increase in O2 consumption, respectively after 3 h. A second dose of rimonabant administered 9–14.5 h after the first one failed to affect O2 consumption, suggesting the development of tolerance. Similarly, stereotypic behaviors and ambulatory activity increased following the first dose but these effects were not observed after the second dose. Respiratory quotients revealed no effect of rimonabant on rates of carbohydrate and fat oxidation. Analysis of the correlation between O2 consumption and physical activity indicated that factors other than increased physical activity may contribute to the increase in O2 consumption. Similar studies in mice demonstrated that wild type but not CB1R−/− mice showed a change in O2 consumption and physical activity following rimonabant administration, suggesting that these effects are mediated by the cannabinoid CB1 receptor.
Conclusion: Previous studies suggested that reduced food intake alone may not explain the weight reduction observed with rimonabant. Our studies suggest that rimonabant stimulates significant acute energy expenditure in non-obese rodents, which could not be completely accounted for by an increase in physical activity. However, with the observation that there is rapid development of tolerance, these results suggest that there may be additional mechanism(s) that lead to weight loss in these rodents.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Pagotto U, Marsicano G, Cota D, Lutz B, Pasquali R . The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocr Rev 2006; 27: 73–100.
Black SC . Cannabinoid receptor antagonists and obesity. Curr Opin Investig Drugs 2004; 5: 389–394.
Meschler JP, Kraichely DM, Wilken GH, Howlett AC . Inverse agonist properties of N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2, 4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide HCl (SR141716A) and 1-(2-chlorophenyl)-4-cyano-5-(4-methoxyphenyl)-1H-pyrazole-3-carboxyl ic acid phenylamide (CP-272871) for the CB(1) cannabinoid receptor. Biochem Pharmacol 2000; 60: 1315–1323.
Rinaldi-Carmona M, Barth F, Heaulme M, Shire D, Calandra B, Congy C et al. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 1994; 350: 240–244.
Colombo G, Agabio R, Diaz G, Lobina C, Reali R, Gessa GL . Appetite suppression and weight loss after the cannabinoid antagonist SR 141716. Life Sci 1998; 63: PL113–PL117.
Poirier B, Bidouard JP, Cadrouvele C, Marniquet X, Staels B, O'Connor SE et al. The anti-obesity effect of rimonabant is associated with an improved serum lipid profile. Diabetes Obes Metab 2005; 7: 65–72.
Ravinet Trillou C, Arnone M, Delgorge C, Gonalons N, Keane P, Maffrand JP et al. Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice. Am J Physiol Regul Integr Comp Physiol 2003; 284: R345–R353.
Verty AN, McGregor IS, Mallet PE . Consumption of high carbohydrate, high fat, and normal chow is equally suppressed by a cannabinoid receptor antagonist in non-deprived rats. Neurosci Lett 2004; 354: 217–220.
Vickers SP, Webster LJ, Wyatt A, Dourish CT, Kennett GA . Preferential effects of the cannabinoid CB1 receptor antagonist, SR 141716, on food intake and body weight gain of obese (fa/fa) compared to lean Zucker rats. Psychopharmacology (Berl) 2003; 167: 103–111.
Despres JP, Golay A, Sjostrom L . Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005; 353: 2121–2134.
Gelfand EV, Cannon CP . Rimonabant: a cannabinoid receptor type 1 blocker for management of multiple cardiometabolic risk factors. J Am Coll Cardiol 2006; 47: 1919–1926.
Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J . Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 2006; 295: 761–775.
Scheen AJ, Finer N, Hollander P, Jensen MD, Van Gaal LF . Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet 2006; 368: 1660–1672.
Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S . Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005; 365: 1389–1397.
Smith RA, Fathi Z . Recent advances in the research and development of CB(1) antagonists. IDrugs 2005; 8: 53–66.
Liu YL, Connoley IP, Wilson CA, Stock MJ . Effects of the cannabinoid CB1 receptor antagonist SR141716 on oxygen consumption and soleus muscle glucose uptake in Lep(ob)/Lep(ob) mice. Int J Obes Relat Metab Disord 2005; 29: 183–187.
Thornton-Jones ZD, Kennett GA, Benwell KR, Revell DF, Misra A, Sellwood DM et al. The cannabinoid CB1 receptor inverse agonist, rimonabant, modifies body weight and adiponectin function in diet-induced obese rats as a consequence of reduced food intake. Pharmacol Biochem Behav 2006; 84: 353–359.
Herling AW, Gossel M, Haschke G, Stengelin S, Kuhlmann J, Muller G et al. CB1 receptor antagonist AVE1625 affects primarily metabolic parameters independently of reduced food intake in Wistar rats. Am J Physiol 2007; 293: E826–E832.
Costa B, Colleoni M . SR141716A induces in rats a behavioral pattern opposite to that of CB1 receptor agonists. Acta Pharmacol Sin 1999; 20: 1103–1106.
Darmani NA, Pandya DK . Involvement of other neurotransmitters in behaviors induced by the cannabinoid CB1 receptor antagonist SR 141716A in naive mice. J Neural Transm 2000; 107: 931–945.
Jarbe TU, DiPatrizio NV, Li C, Makriyannis A . The cannabinoid receptor antagonist SR-141716 does not readily antagonize open-field effects induced by the cannabinoid receptor agonist (R)-methanandamide in rats. Pharmacol Biochem Behav 2003; 75: 809–821.
Compton DR, Aceto MD, Lowe J, Martin BR . In vivo characterization of a specific cannabinoid receptor antagonist (SR141716A): inhibition of delta 9-tetrahydrocannabinol-induced responses and apparent agonist activity. J Pharmacol Exp Ther 1996; 277: 586–594.
Masserano JM, Karoum F, Wyatt RJ . SR 141716A, a CB1 cannabinoid receptor antagonist, potentiates the locomotor stimulant effects of amphetamine and apomorphine. Behav Pharmacol 1999; 10: 429–432.
Navarro M, Hernandez E, Munoz RM, del Arco I, Villanua MA, Carrera MR et al. Acute administration of the CB1 cannabinoid receptor antagonist SR 141716A induces anxiety-like responses in the rat. Neuroreport 1997; 8: 491–496.
Ibrahim MM, Deng H, Zvonok A, Cockayne DA, Kwan J, Mata HP et al. Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS. Proc Natl Acad Sci USA 2003; 100: 10529–10533.
Even PC, Mokhtarian A, Pele A . Practical aspects of indirect calorimetry in laboratory animals. Neurosci Biobehav Rev 1994; 18: 435–447.
Simonson DC, DeFronzo RA . Indirect calorimetry: methodological and interpretative problems. Am J Physiol 1990; 258: E399–E412.
Fruebis J, Tsao TS, Javorschi S, Ebbets-Reed D, Erickson MR, Yen FT et al. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci USA 2001; 98: 2005–2010.
Gil-Campos M, Canete RR, Gil A . Adiponectin, the missing link in insulin resistance and obesity. Clin Nutr 2004; 23: 963–974.
Sethi JK, Vidal-Puig A . Visfatin: the missing link between intra-abdominal obesity and diabetes? Trends Mol Med 2005; 11: 344–347.
Perwitz N, Fasshauer M, Klein J . Cannabinoid receptor signaling directly inhibits thermogenesis and alters expression of adiponectin and visfatin. Horm Metab Res 2006; 38: 356–358.
Bensaid M, Gary-Bobo M, Esclangon A, Maffrand JP, Le Fur G, Oury-Donat F et al. The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol Pharmacol 2003; 63: 908–914.
Gary-Bobo M, Elachouri G, Scatton B, Le Fur G, Oury-Donat F, Bensaid M . The cannabinoid CB1 receptor antagonist rimonabant (SR141716) inhibits cell proliferation and increases markers of adipocyte maturation in cultured mouse 3T3 F442A preadipocytes. Mol Pharmacol 2006; 69: 471–478.
Stefan N, Vozarova B, Funahashi T, Matsuzawa Y, Ravussin E, Weyer C et al. Plasma adiponectin levels are not associated with fat oxidation in humans. Obes Res 2002; 10: 1016–1020.
Jbilo O, Ravinet-Trillou C, Arnone M, Buisson I, Bribes E, Peleraux A et al. The CB1 receptor antagonist rimonabant reverses the diet-induced obesity phenotype through the regulation of lipolysis and energy balance. FASEB J 2005; 19: 1567–1569.
Rubino T, Vigano D, Zagato E, Sala M, Parolaro D . In vivo characterization of the specific cannabinoid receptor antagonist SR141716A: behavioral and cellular responses after acute and chronic treatments. Synapse 2000; 35: 8–14.
Engeli S, Jordan J . The endocannabinoid system: body weight and metabolic regulation. Clin Cornerstone 2006; 8 (Suppl 4): S24–S35.
Engeli S, Bohnke J, Feldpausch M, Gorzelniak K, Janke J, Batkai S et al. Activation of the peripheral endocannabinoid system in human obesity. Diabetes 2005; 54: 2838–2843.
Matias I, Di Marzo V . Endocannabinoids and the control of energy balance. Trends Endocrinol Metab 2007; 18: 27–37.
Doyon C, Denis RG, Baraboi ED, Samson P, Lalonde J, Deshaies Y et al. Effects of rimonabant (SR141716) on fasting-induced hypothalamic-pituitary-adrenal axis and neuronal activation in lean and obese Zucker rats. Diabetes 2006; 55: 3403–3410.
Acknowledgements
We thank Dr Laurence Ozmen for providing the CB1R−/− mice, Dr Stephan Roever for providing the in-house synthesized compound rimonabant, Dr Thomas Mindt and Dr Uwe Totzke for their valuable contributions, and Joseph Schoerlin, Nadine Petit and Anthony Vandjour for excellent technical help.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kunz, I., Meier, M., Bourson, A. et al. Effects of rimonabant, a cannabinoid CB1 receptor ligand, on energy expenditure in lean rats. Int J Obes 32, 863–870 (2008). https://doi.org/10.1038/ijo.2008.3
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ijo.2008.3
Keywords
This article is cited by
-
Effects of endocannabinoids on feed intake, stress response and whole-body energy metabolism in dairy cows
Scientific Reports (2021)
-
Metabolic responses to long-term pharmacological inhibition of CB1-receptor activity in mice in relation to dietary fat composition
International Journal of Obesity (2010)
-
The Endocannabinoid System: Potential for Reducing Cardiometabolic Risk
Obesity (2009)